Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Northwest BiotherapeuticsLTS:0K95 11 EV-to-EBITDA is -14.57 as of Aug. 29, 2026. GuruFocus rates LTS:0K95 with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 414 Biotechnology companies, Northwest Biotherapeutics ranks worse than 241545.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Northwest Biotherapeutics's enterprise value is £278.93 Mil.
Northwest Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was £-19.14 Mil. Therefore, Northwest Biotherapeutics's EV-to-EBITDA for today is -14.57.
The historical rank and industry rank for Northwest Biotherapeutics's EV-to-EBITDA or its related term are showing as below:
LTS:0K95'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.32 Med: -4.93 Max: 41.63
Current: -14.73
During the past 13 years, the highest EV-to-EBITDA of Northwest Biotherapeutics was 41.63. The lowest was -21.32. And the median was -4.93.
LTS:0K95's EV-to-EBITDA is ranked worse than 100% of 414
companies
in the Biotechnology industry
Industry Median: 13.55
vs LTS:0K95: -14.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Northwest Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Northwest Biotherapeutics's share price for today is £2.40.
Northwest Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £-0.023.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0K95 vs FATE, IMRX, FHTX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Northwest Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's EV-to-EBITDA falls into.
Northwest Biotherapeutics's current Enterprise Value is £278.93 Mil.
Northwest Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £-19.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (LTS:0K95) has a EV-to-EBITDA of -14.57 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Northwest Biotherapeutics. According to the industry distribution chart, Northwest Biotherapeutics ranks #999999 out of 414 companies in the Biotechnology industry.
Is Northwest Biotherapeutics' EV-to-EBITDA too high?
Northwest Biotherapeutics' current EV-to-EBITDA is -14.57. Based on the distribution chart, Northwest Biotherapeutics ranks #999999 out of 414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' EV-to-EBITDA compare to FATE and IMRX?
According to the Biotechnology industry distribution chart, Northwest Biotherapeutics ranks #999999 out of 414 companies for EV-to-EBITDA. This places Northwest Biotherapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.55, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Northwest Biotherapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Northwest Biotherapeutics's current EV-to-EBITDA is -14.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (LTS:0K95) has a current EV-to-EBITDA of -14.57. The current EV-to-EBITDA is -14.57. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Northwest Biotherapeutics (LTS:0K95), the current EV-to-EBITDA is -14.57 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score
Get the complete analysis for LTS:0K95
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K95 has been successfully added to your 
